Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1929MR)

This product GTTS-WQ1929MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species synthetic construct
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1929MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15115MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ12741MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ10731MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ15561MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ7293MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ8227MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ15567MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ3710MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW